Takeda to Maintain Drug Pricing Model Despite Trump Pressure

Japan’s largest drugmaker, Takeda Pharmaceuticals, said it will maintain its existing pricing model in the U.S., despite President Donald Trump’s call for drug companies to lower their prices.

The company’s CEO, Christophe Weber, told reporters at a Jan. 31 briefing the company’s prices have been reasonable for years, and it is committed to single-digit annual increases.

Takeda produces several cancer treatments and earns about 30 percent of its drug revenue from the U.S.